Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

CHRS - Coherus Oncology, Inc. Последние новости | Finranks

Home

/

CHRS

C

Coherus Oncology, Inc. (CHRS)

NGM – Цена в реальном времени. Валюта: USD

1.17

-0.04 (-2.89%)

Рынок открыт: Aug 12, 2026, 3:15 PM EDT

1.21

0.00 (0.00%)

Предыдущая сессия: Aug 11, 2026, 7:34 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Coherus Oncology, Inc. (CHRS) Q2 2026 Earnings Call Transcript

Coherus Oncology, Inc. (CHRS) Q2 2026 Earnings Call Transcript

Coherus Oncology, Inc. (CHRS) Q2 2026 Earnings Call Transcript

Coherus Oncology Q2 Earnings Call Highlights

Coherus Oncology Q2 Earnings Call Highlights

Coherus Oncology NASDAQ: CHRS said it is approaching several clinical data disclosures in the second half of 2026, while reporting continued growth for its LOQTORZI treatment and lower operating expenses following the divestiture of its UDENYCA franchise.

Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates

Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates

Coherus Oncology (CHRS) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of $0.08. This compares to a loss of $0.34 per share a year ago.

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – – Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer – – Projected October public disclosure of data sets with sufficient maturity – – Conference call today at 5:00 p.m. Eastern Daylight Time – REDWOOD CITY, Calif.

Видео

No Data

There is no data to display

Пресс-релизы

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – – Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer – – Projected October public disclosure of data sets with sufficient maturity – – Conference call today at 5:00 p.m. Eastern Daylight Time – REDWOOD CITY, Calif.